Compare GCBC & NGNE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GCBC | NGNE |
|---|---|---|
| Founded | 1889 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 374.8M | 327.8M |
| IPO Year | 1998 | N/A |
| Metric | GCBC | NGNE |
|---|---|---|
| Price | $23.78 | $17.38 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $40.14 |
| AVG Volume (30 Days) | 11.7K | ★ 111.0K |
| Earning Date | 01-21-2026 | 03-23-2026 |
| Dividend Yield | ★ 1.65% | N/A |
| EPS Growth | ★ 39.39 | N/A |
| EPS | ★ 2.15 | N/A |
| Revenue | ★ $81,989,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $11.08 | ★ N/A |
| Revenue Growth | ★ 24.51 | N/A |
| 52 Week Low | $20.00 | $6.88 |
| 52 Week High | $27.62 | $37.27 |
| Indicator | GCBC | NGNE |
|---|---|---|
| Relative Strength Index (RSI) | 49.28 | 45.98 |
| Support Level | $23.55 | $16.20 |
| Resistance Level | $24.42 | $17.95 |
| Average True Range (ATR) | 0.62 | 1.36 |
| MACD | 0.01 | 0.02 |
| Stochastic Oscillator | 37.74 | 34.81 |
Greene County Bancorp Inc is a holding firm. Its primary business involves overseeing and directing the business of The Bank of Greene County and monitoring its cash position. Through its directly and indirectly owned subsidiaries, the company engages in attracting retail deposits, along with funds generated from operations and borrowings, predominantly in one to four-family residential mortgage loans, commercial real estate mortgage loans, consumer loans, home equity loans, and commercial business loans. It also serves local municipalities' banking needs and operates a real estate investment trust.
Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACTTM (Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.